These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 27057126

  • 21. Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial.
    Porter J, Bowden DK, Economou M, Troncy J, Ganser A, Habr D, Martin N, Gater A, Rofail D, Abetz-Webb L, Lau H, Cappellini MD.
    Anemia; 2012; 2012():297641. PubMed ID: 22924125
    [Abstract] [Full Text] [Related]

  • 22. Cost-Utility Analysis of four Chelation Regimens for β-thalassemia Major: a Chinese Perspective.
    Li J, Wang P, Li X, Wang Q, Zhang J, Lin Y.
    Mediterr J Hematol Infect Dis; 2020; 12(1):e2020029. PubMed ID: 32395218
    [Abstract] [Full Text] [Related]

  • 23. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.
    Aydinok Y, Unal S, Oymak Y, Vergin C, Türker ZD, Yildiz D, Yesilipek A.
    Eur J Haematol; 2012 May; 88(5):431-8. PubMed ID: 22335829
    [Abstract] [Full Text] [Related]

  • 24. Economic Evaluation of Chelation Regimens for β-Thalassemia Major: a Systematic Review.
    Li J, Lin Y, Li X, Zhang J.
    Mediterr J Hematol Infect Dis; 2019 May; 11(1):e2019036. PubMed ID: 31308912
    [Abstract] [Full Text] [Related]

  • 25. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E, Agapidou A, Spanos G, Klonizakis P, Vetsiou E, Mavroudi M, Boura P.
    Hemoglobin; 2015 May; 39(5):299-304. PubMed ID: 26177199
    [Abstract] [Full Text] [Related]

  • 26. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [Abstract] [Full Text] [Related]

  • 27. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, Lordan N, Ishak K, Proskorovsky I.
    Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
    Dou H, Qin Y, Chen G, Zhao Y.
    Acta Haematol; 2019 Aug; 141(1):32-42. PubMed ID: 30504715
    [Abstract] [Full Text] [Related]

  • 29. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
    Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M.
    Curr Med Res Opin; 2018 Nov; 34(11):1959-1966. PubMed ID: 29701080
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R, Ahmed J, Krishnan P, Jankharia B.
    Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 32. Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major.
    Karami H, Kosaryan M, Amree AH, Darvishi-Khezri H, Mousavi M.
    Clin Pract; 2017 Jan 11; 7(1):912. PubMed ID: 28243431
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Jan 11; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 34. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY, Li Q, Chen JJ, Chen GF, Li CG.
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul 11; 13(7):531-4. PubMed ID: 21752315
    [Abstract] [Full Text] [Related]

  • 35. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.
    J Clin Pharm Ther; 2012 Apr 11; 37(2):173-81. PubMed ID: 21592159
    [Abstract] [Full Text] [Related]

  • 36. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 11; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 37. Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?
    Mattioli F, Puntoni M, Marini V, Fucile C, Milano G, Robbiano L, Perrotta S, Pinto V, Martelli A, Forni GL.
    Eur J Haematol; 2015 Apr 11; 94(4):310-7. PubMed ID: 25081908
    [Abstract] [Full Text] [Related]

  • 38. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan 11; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 39. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Jan 11; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 40. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
    Tsouana E, Kaya B, Gadong N, Hemmaway C, Newell H, Simmons A, Whitmarsh S, Telfer P.
    Eur J Haematol; 2015 Apr 11; 94(4):336-42. PubMed ID: 25138173
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.